Anzeige
Mehr »
Login
Dienstag, 14.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Die 1 Billionen Dollar Mine: Power Nickels Weg zur globalen Dominanz!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JBVH | ISIN: FR0011052257 | Ticker-Symbol: 1DK
Frankfurt
13.01.25
08:09 Uhr
1,354 Euro
+0,170
+14,36 %
1-Jahres-Chart
GLOBAL BIOENERGIES Chart 1 Jahr
5-Tage-Chart
GLOBAL BIOENERGIES 5-Tage-Chart
RealtimeGeldBriefZeit
1,1921,69213.01.
GlobeNewswire (Europe)
191 Leser
Artikel bewerten:
(1)

Unable to get its cosmetics plant project financed, Global Bioenergies is now focusing all its efforts on SAF opportunities

Finanznachrichten News

PRESS RELEASE

Unable to get its cosmetics plant project financed, Global Bioenergies is now focusing all its efforts on SAF opportunities

Evry, 17 October 2024 - 07:30 a.m.: After several months of efforts, the Company has been unable to find investors for its 2,500-ton plant dedicated to the cosmetics market, in a highly unfavorable context for the financing of first-of-a-kind projects. The Company is now devoting all its energy to applying its technology to the production of Sustainable Aviation Fuel ("SAF"), with a model of industrial partnerships.

Samuel Dubruque, Chief Financial Officer of Global Bioenergies, commented: "Despite all our efforts over the last few months, and with the conviction that we have presented the most mature case possible, we are now coming to the conclusion that our plant project will not reach final investment decision. Like all first-of-a-kinds, this project necessarily involves risks at various levels. The prospect of a significant return on investment linked to the cosmetics market should have been a sufficient counterbalance, allowing us to convince private investors to commit to the project, but we must realize that this is not the case in the current political, economic and financial context. Today, infrastructure investors limit themselves to less risky industrial replica projects1, and to projects more directly focused on energy markets."

Marc Delcourt, co-founder and Chief Executive Officer, added: "Global Bioenergies regrets that this project is not moving forward, and draws the necessary conclusions: the Company will therefore not be carrying out any plant projects of its own in the short or medium term, and will be focusing all its efforts on a partnership model. The intrinsic value of the process developed by Global Bioenergies is not diminished by the non-realization of this first industrial project designed to meet the needs of the niche cosmetics market. Our main ambition remains to produce much larger volumes of SAF, in order to reduce the carbon footprint of the aviation sector and fight global warming, now an absolute priority. To achieve this, the technology partnership approach is the most appropriate."

As a reminder, the Company's process is one of only a dozen solutions to have obtained ASTM certification. The SAF market is currently in the start-up phase, and will really accelerate in 2030, when the European mandate increases to 6% (i.e. around 3 million tons/year) and production in the United States reaches the "Grand Challenge" target of 3 billion gallons per year (i.e. 9 million tons/year)2. The Company still aims to contribute to achieving these 2030 objectives on both sides of the Atlantic. Alongside this future large-scale SAF production, the Company intends to continue serving niche markets, in particular cosmetics.

About GLOBAL BIOENERGIES

As a committed player in the fight against global warming, Global Bioenergies has developed a unique process to produce SAF and e-SAF from renewable resources, thereby meeting the challenges of decarbonising air transport. Its technology is one of the very few solutions already certified by ASTM. Its products also meet the high standards of the cosmetics industry, and L'Oréal is its largest shareholder with a 13.5% stake. Global Bioenergies is listed on Euronext Growth in Paris (FR0011052257 - ALGBE).

Contacts



GLOBAL BIOENERGIES
+33 (0)1 64 98 20 50
invest@global-bioenergies.com



Follow our news



Receive information about Global Bioenergies directly by subscribing to our news feed on https://www.global-bioenergies.com/inscription-newsletter/



Follow us on LinkedIn
Global Bioenergies





NewCap - Investor relations

Louis-Victor Delouvrier
Aurélie Manavarere
globalbioenergies@newcap.eu

+33 (0)1 44 71 94 94



NewCap - Media relations



Nicolas Merigeau
globalbioenergies@newcap.eu
+33 (0)1 44 71 94 98

1 Réussir le passage à l'échelle des cleantech en France (website-files.com) - Cleantech for France (in French
2 Sustainable Aviation Fuel Market Outlook - June 2024, SkyNRG


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.